Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FGGQ2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $7,495
Award facts
- Contract value 100% obligated
- $7,495.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $7,495.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Dupixent (dupilumab) 300 mg/2 mL pens. The delivery order, issued on January 23, 2026, with an ultimate completion date of January 26, 2026, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was selected under its single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors for the Department of Defense's pharmaceutical supply chain.
The PPV-G GEN V contract awarded to DMS Pharmaceutical Group, designated SPE2DR and valued at $499,999,999, positions the company as a critical pharmaceutical supplier for Department of Defense healthcare operations globally. The underlying IDC, awarded on November 13, 2025, features a 30-month base period with three 30-month option periods extending through December 31, 2036, and authorizes the agency to issue firm fixed-price delivery orders for branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous delivery orders and its comprehensive product portfolio spanning oncology treatments, immunosuppressants, vaccines, and specialty pharmaceuticals demonstrate its capability to fulfill the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FGGQ2?
SPE2DR26FGGQ2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FGGQ2 worth?
The government has obligated $7,495 on SPE2DR26FGGQ2.
Is contract SPE2DR26FGGQ2 an order under another contract?
Yes. SPE2DR26FGGQ2 is a delivery order under SPE2DR25D9349, an indefinite delivery contract.
Was contract SPE2DR26FGGQ2 competed?
The extent of competition for SPE2DR26FGGQ2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award